西洛他唑联合氯吡格雷治疗心肌梗死临床评价
|
摘要
目的探讨西洛他唑联合氯吡格雷治疗心肌梗死的疗效及对血浆肌酸激酶同工酶(CK-MB)、心肌肌钙蛋白(cTnT)水平的影响。方法选取医院2016年4月至2017年5月收治的心肌梗死患者96例,按随机数字表法分为观察组和对照组,各48例。对照组患者给予阿司匹林联合氯吡格雷治疗,观察组患者给予西洛他唑联合氯吡格雷治疗,均持续用药3个月。结果观察组总有效率为93.75%,明显高于对照组的79.17%(P <0.05);治疗期间,观察组患者主要心血管不良事件发生率明显低于对照组(P <0.05);治疗后,两组患者血浆CK-MB及cTnT水平均明显降低,且观察组降低幅度更大(P <0.05)。结论西洛他唑联合氯吡格雷治疗心肌梗死疗效确切,能有效降低心血管不良事件的发生率,减轻心肌损伤。
Objective To investigate the clinical effect of cilostazol combined with clopidogrel in the treatment of myocardial infarction and its effect on the levels of plasma creatine kinase isoenzyme(CK-MB),cardiac troponin T(cTnT).Methods Totally 96 patients with myocardial infarction admitted to our hospital from April 2016 to May 2017 were selected and divided into the observation group and the control group by the random number table method,48 cases in each group.The patients in the control group were treated with aspirin combined with clopidogrel,while the patients in the observation group were treated with cilostazol combined with clopidogrel.Both groups were treated for 3 months.Results The total effective rate of the observation group was 93.75%,which was significantly higher than 79.17% of the control group(P < 0.05).During the treatment period,the incidence rate of major adverse cardiovascular events in the observation group was significantly lower than that in the control group(P < 0.05).After treatment,the levels of plasma CK-MB and cTnT in the two groups were significantly decreased,and the decrease in the observation group was more significant(P < 0.05).Conclusion Cilostazol combined with clopidogrel is effective in the treatment of myocardial infarction,which can effectively reduce the incidence of cardiovascular adverse events and reduce myocardial injury of patients.
Objective To investigate the clinical effect of cilostazol combined with clopidogrel in the treatment of myocardial infarction and its effect on the levels of plasma creatine kinase isoenzyme(CK-MB),cardiac troponin T(cTnT).Methods Totally 96 patients with myocardial infarction admitted to our hospital from April 2016 to May 2017 were selected and divided into the observation group and the control group by the random number table method,48 cases in each group.The patients in the control group were treated with aspirin combined with clopidogrel,while the patients in the observation group were treated with cilostazol combined with clopidogrel.Both groups were treated for 3 months.Results The total effective rate of the observation group was 93.75%,which was significantly higher than 79.17% of the control group(P < 0.05).During the treatment period,the incidence rate of major adverse cardiovascular events in the observation group was significantly lower than that in the control group(P < 0.05).After treatment,the levels of plasma CK-MB and cTnT in the two groups were significantly decreased,and the decrease in the observation group was more significant(P < 0.05).Conclusion Cilostazol combined with clopidogrel is effective in the treatment of myocardial infarction,which can effectively reduce the incidence of cardiovascular adverse events and reduce myocardial injury of patients.
引文
[1]中华医学会.临床诊疗指南·心血管分册[M].北京:人民卫生出版社,2008:70.
[2]张庆胜.急诊介入对急性心肌梗死的疗效分析[J].吉林医学,2012,33(3):459-460.
[3]LYNGBAEK S,ANDERSSON C,MAROTT JL,et al.Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain[J].Clin Chem,2013,59(11):1621-1629.
[4]陈琳,于春玲,左晓春,等.氯吡格雷对急性前壁性心肌梗死患者PCI的疗效及安全性分析[J].现代医学,2017,45(6):777-781.
[5]王炳理.氯吡格雷联合尿激酶治疗急性ST段抬高型心肌梗死观察[J].现代临床医学,2016,42(4):285-286.
[6]司清霞.尿激酶、阿司匹林、氯吡格雷治疗ST段抬高心肌梗死70例[J].临床医学,2012,32(12):96-97.
[7]涂强.西洛他唑的药理作用机制及其临床应用的研究进展[J].中国动脉硬化杂志,2017,25(6):644-648.
[8]王冲.肌酸激酶同工酶联合肌红蛋白,肌钙蛋白对急性心肌梗死的快速诊断价值[J].中国卫生标准管理,2015,6(27):144-145.
[9]REYES DRA.Caracterización del infarto agudo del micardio en Venezuela durante el a o 2008[J].Cor Salud,2010,2(1):45-54.
[10]贾凤玖,姚卫华,赵青山.参麦注射液和丹红注射液联合应用对急性心肌梗死患者肌钙蛋白T的影响[J].中西医结合心脑血管病杂志,2013,11(11):1384-1385.
[2]张庆胜.急诊介入对急性心肌梗死的疗效分析[J].吉林医学,2012,33(3):459-460.
[3]LYNGBAEK S,ANDERSSON C,MAROTT JL,et al.Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain[J].Clin Chem,2013,59(11):1621-1629.
[4]陈琳,于春玲,左晓春,等.氯吡格雷对急性前壁性心肌梗死患者PCI的疗效及安全性分析[J].现代医学,2017,45(6):777-781.
[5]王炳理.氯吡格雷联合尿激酶治疗急性ST段抬高型心肌梗死观察[J].现代临床医学,2016,42(4):285-286.
[6]司清霞.尿激酶、阿司匹林、氯吡格雷治疗ST段抬高心肌梗死70例[J].临床医学,2012,32(12):96-97.
[7]涂强.西洛他唑的药理作用机制及其临床应用的研究进展[J].中国动脉硬化杂志,2017,25(6):644-648.
[8]王冲.肌酸激酶同工酶联合肌红蛋白,肌钙蛋白对急性心肌梗死的快速诊断价值[J].中国卫生标准管理,2015,6(27):144-145.
[9]REYES DRA.Caracterización del infarto agudo del micardio en Venezuela durante el a o 2008[J].Cor Salud,2010,2(1):45-54.
[10]贾凤玖,姚卫华,赵青山.参麦注射液和丹红注射液联合应用对急性心肌梗死患者肌钙蛋白T的影响[J].中西医结合心脑血管病杂志,2013,11(11):1384-1385.